Recent developments in biomarkers used for evaluation of juvenile idiopathic arthritis

Современные разработки биомаркеров используемые для оценки идиопатического ювенильного артрита
Tuba Tülay Koca 1, Aydın Arslan 2
More Detail
1 Malatya State Hospital, Physical Medicine and Rehabilitation Clinic, Malatya, Turkey
2 Malatya State Hospital, Orthopaedics and Traumatology Clinic, Malatya, Turkey
J CLIN MED KAZ, Volume 1, Issue 35, pp. 11-14.
OPEN ACCESS 4025 Views 2862 Downloads
Download Full Text (PDF)

ABSTRACT

Juvenile idiopathic arthritis (JIA) is the most common inflammatory disease in childhood. JIA is subdivided into six categories, all of which differ in etiological factors, clinical phenotype, prognosis, laboratory tests and response to therapy. To start appropriate treatment in patients with JIA and to inform patients correctly, it is essential to know the individual prognosis. This emphasizes the need for research on novel and more accurate biomarkers to assess disease acitivity. A biomarker comprises small samples from the patient such as blood, urine and saliva, obtained by non-invasive techniques. These serum biomarkers such as S100 proteins (S100A12,S1008/9), myelin related proteins (MRP8/14), single nucleotide polymorphism (SNPs) and newly vectra DA have been suggested for the prediction of disease course and relapse risk. İn this review we summarize the biomarkers for JIA.
Keywords: biomarker, juvenil idiopathic arthritis

CITATION

Koca TT, Arslan A. Recent developments in biomarkers used for evaluation of juvenile idiopathic arthritis. Journal of Clinical Medicine of Kazakhstan. 2015;1(35):11-4.

REFERENCES

  • Ravelli A, Martini A. Juvenile idiopathic arthritis, Lancet, 2007, No.369(9563), pp.767-778.
  • Klassen TP, Hartling L. Craig JG. Children are not just small adults. The urgent need for high-quality trial evidence in children, PLoS Med, 2008, No. 5(8), p.e172.
  • Barton A, Worthington J. Genetic suspectibility to rheumatoid arthritis: an emerging picture, Arthritis Rheum, 2009, No. 61(10), pp.1441-1446
  • Hinks A, Ke X, Barton A, Eyre S, Bowes J, Worthington J, et al. Association of the IL2RA/CD25 gene with juvenile idiopathic arthritis, Arthritis Rheum, 2009, No.60(1), pp.251-257. 
  • Scola MP, Imagawa T, Boivin GP, Giannini Eh, Glass Dn, Hirsch R, et al. Expression of angiogenic factors in juvenile rheumatoid arthritis: correlation with revascularization of human synovium engrafted into SCID mice, Arthritis Rheum, 2001, No.44(4), pp.794-801.
  • Gerss J, Roth J, Holzinger D, Ruperto N, Wittkowski H, et al. Phagocyte-specific S100 proteins and high-sensitivity C-reactive protein as biomarkers for risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study, Ann Rheum Dis, 2012, No.71(12), pp. 1991-1997.
  • Foell D, Roth J. Proinflammatory protein S100 proteins in arthritis and autoimmun disease, Arthritis Rheum, 2004, No. 50(12), pp.3762-3771.
  • Holzinger D, Frosch M, Kastrup A, et al. The toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic on-set juvenile idiopathic arthritis, Ann Rheum Dis, 2012, No.71(6), pp.974- 980.
  • Wittkowski H, Frosch M, Wulffraat N, et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin, Arthritis Rheum, 2008, No.58(12), pp. 3924-3931.
  • Thomson W, Barett JH, Donn R, et al. Juvenil idiopathic arthritis clasified by ILAR criteria: HLA association in UK patients, Rheumatology(Oxford), 2002, No.41, pp.1183-1189.
  • Angeles-Han ST, Pelajo CF, Vogler LB, et al. Risk Markers of Juvenile İdiopathic Arthrit-associated Üveitis in the Childhood Arthritis and Rheumatology Research Alliance(CARRA) registry, Journal Rheumatology, 2013.
  • Ravelli A, Gromm AA, Behrens EM, et al. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathopysiology and treatment, Genes Immunol, 2012, 13(4), pp.289-298.
  • Moore Tl, Gillian BE, Crespo-Pagnussat S, Feller L, Chauhan Ak. Measurement and evaluation of isotypes of anti-citrullinated fibrinogen and anti-citrullinated alpha-enolase antibodies in juvenile idiopathic arthitis, Clin Exp Rheumatol, 2014, Jul 17. (Epub ahead of print)
  • Nistala K, Moncrieffe H, Newton KR, et al. Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a resiprocal relationship to regulatory T cell numbers, Arthritis Rheum, 2008, No.58(3), pp.875-887.
  • Gibson DS, Finnegan S, Jordan G, et al. Stratification and Monitoring of Juvenile İdiopathic Arthritis Patients by Synovial Proteoma Analysis, J. Proteoma Res, 2009, No.8, pp.5601-5609.
  • Hinks A, Moncrieffe H, Martin P, et al. Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis, Ann Rheum Dis, 2011, No.70(8), pp.1395-1400.
  • Jiang K, Frank Mb, Chen Y, et al. Genomic characterization of remission in juvenile rheumatoid arthritis, Arthritis Res Ther, 2013, No.15(4), p.100.
  • Ringoid S, Lu L, Wallace Ca, Sasso Eh, Scott Eastman P. Program and abstracts of the European League Against Rheumatism (EULAR) congress 2014, June 11-14, 2014,Paris, France, Abstract FRI0556.
  • Ringoid S, Lu L, Wallace Ca, Sasso Eh, Scott Eastman P. A7: İnitial Assesment of Multi-biomarker Disease Activity Assay İn JIA, Arhtritis Rheumatol, 2014, No.66(11), pp.10-11.
  • Van Dijkhuizen Eh, Wulffraat Nm. Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature review, Ann Rheum Dis, 2014 Jun 24. pii:annrheumdis-2014-205265. doi: 10.1136/annrheumdis-2014-205265.